Cryptic deletion of EGR1 in association with a novel balanced t(5;22)(q31;q11.2) in a patient with myelodysplastic syndrome

Cancer Genetics and Cytogenetics

Volumn 191, Issue 2, 2009, Pages 106-108

  Hoffman, Matthew W ^a   Janney, Stephen ^b   Batanian, Jacqueline R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b St Mary's Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1;

AGED; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 22; CHROMOSOME 22Q; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME TRANSLOCATION; EOSINOPHIL COUNT; ERYTHROBLAST; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE PROBE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LYMPHOCYTE COUNT; MEGAKARYOCYTE; MICROSCOPY; MONOCYTE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMYELOCYTE; THROMBOCYTE COUNT;

AGED; BONE MARROW; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 5; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MEGAKARYOCYTES; MYELODYSPLASTIC SYNDROMES; TRANSLOCATION, GENETIC;

EID: 65549102136     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.02.008     Document Type: Article

References (15)

1. Van den Berghe H., Cassiman J.J., David G., Fryns J.P., Michaux J.L., and Sokal G. Distinct haematological disorder with deletion of long arm of the no. 5 chromosome. Nature 251 (1974) 437-438
2. Rowley J.D., Golomb H.M., and Vardiman J.W. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 58 (1981) 759-767
3. Thirman M.J., and Larson R.A. Therapy-related myeloid leukemia. Hematology/Oncology Clinics of North America 10 (1996) 293-320
4. Haase D., Fonatsch C., Freund M., Wormann B., Bodenstein H., Bartels H., Stollmann-Gibbels B., and Lengfelder E. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 70 (1995) 171-187
5. Michalova K., Musilova J., and Zemanova Z. Cytogenetic abnormalities in 532 patients with myeloid leukemias and myelodysplastic syndrome. Czech Med 13 (1990) 133-144
6. Joslin J.M., Fernald A.A., Tennant T.R., Davis E.M., Kogan S.C., Anastasi J., Crispino J.D., and Le Beau M. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 110 (2007) 719-726
7. Krones-Herzig A., Adamson E., and Mercola D. Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci USA 100 (2003) 3233-3238
8. Rosati R., La Starza R., Barba G., Gorello P., Pierini V., Matteucci C., Roti G., Crescenzi B., Romoli S., Aloisi T., Aversa F., Fabrizio Martelli M., and Mecucci C. Cryptic chromosome 9q34 deletion generates TAF-Iα/CAN and TAF-Iß/CAN fusion transcripts in acute myeloid leukemia. Haematologica 92 (2007) 232-235
9. Reddy K., Satyadev R., Bouman D., Hibbard M.K., Lu G., and Paolo R. Burkitt t(8;14)(q24;q32) and cryptic deletion in a CLL patient: report of a case and review of literature. Cancer Genet Cytogenet 166 (2006) 12-21
10. Batanian J.R., Huang Y., and Fallon R. Deletion of 3'-CBFB gene in association with an inversion (16)(p13q22) and a loss of the Y chromosome in a 2-year-old child with acute myelogenous leukemia-M4. Cancer Genet Cytogenet 121 (2000) 216-219
11. Batanian J.R., Bridge J.A., Wickert R., Vogler C., Gadre B., and Huang Y. EWS/FLI-1 fusion signal inserted into chromosome 11 in one patient with morphologic features of Ewing sarcoma, but lacking t(11;22). Cancer Genet Cytogenet 133 (2000) 72-75
12. Crescenzi B., La Straza R., Romoli S., Beacci D., Maateuci C., Barba G., Aventin A., Marynen P., Ciolli S., Nozzoli C., Fabrizio Martelli M., and Mecucci C. Submicroscopic deletions in 5q- associated malignancies. Haematologica 89 (2004) 281-285
13. Zou Y.S., Fink S.R., Stockcro K.J., Paternoster S.F., Smoley S.A., Tun H.W., Reeder C.B., Tefferi A., and Dewald G.W. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. Leuk Res 31 (2007) 1185-1189
14. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., Powell B., Greenberg P., Thomas D., Stone R., Reeder C., Wride K., Patin J., Schmidt M., Zeldis J., and Knight R. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
15. Atlas of Genetics and Cytogenetics in Oncology and Hematology. http://www.atlasgeneticsoncology.org/Indexbychrom Accessed March 2009